Clinical Trials Logo

Clinical Trial Summary

Most of the cystic fibrosis (CF) patients are or have been pulmonary colonized with bacteria such as Pseudomonas aeruginosa or Staphylococcus aureus. Aim of this study is to detect virulence factor neutralizing antibodies in the sera of the study population followed by B cell repertoire analyses to design B cell-derived neutralizing monoclonal antibodies. The functionality of neutralizing antibodies rests on inhibition of virulence factors by binding of crucial epitopes rather than merely the induction of opsonization. Focusing on patients with bacterial colonization/chronic infections or a history of an acute infection in the past, will increase the likelihood for identification of serum with neutralizing activity as in vivo antigen contact is a prerequisite for antibody development and maturation. Since virulence factors are essential for infection, dissemination and tissue damage, inhibition of these factors by developed neutralizing antibodies might contribute to a favorable outcome of life-threatening infections.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04700358
Study type Observational
Source University Hospital of Cologne
Contact Alexander Simonis
Phone +4922147889608
Email alexander.simonis@uk-koeln.de
Status Recruiting
Phase
Start date October 1, 2020
Completion date December 31, 2027

See also
  Status Clinical Trial Phase
Completed NCT02566044 - Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis Phase 1/Phase 2
Recruiting NCT04157361 - Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
Recruiting NCT04096664 - Home Airway Clearance in CF Patients N/A
Completed NCT04095078 - Ancillary Home Airway Clearance in CF Patients ( HomeCareSIMEOX ) N/A
Completed NCT02781610 - Standardized Treatment of Pulmonary Exacerbations II Phase 4
Completed NCT02853175 - Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis